ReviewOncoimmunology
Immunotherapies targeting CD38 in Multiple Myeloma.
Review in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma.Hematological oncology · 2023Trial
- Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study.Japanese journal of clinical oncology · 2022Trial
- Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy.Annals of hematology · 2026Review
- Efficacy and safety of daratumumab-based quadruplet therapy vs non-daratumumab-based triplet therapy in newly diagnosed multiple myeloma patients: A GRADE assessed systematic review and meta-analysis of randomized controlled trials.Therapeutic advances in hematology · 2026Article
- A second-generation CD38-CAR-T cell for the treatment of multiple myeloma.Cancer medicine · 2023Article
- Expanding anti-CD38 immunotherapy for lymphoid malignancies.Journal of experimental & clinical cancer research : CR · 2022Article
- High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.Journal of experimental & clinical cancer research : CR · 2022Article
- CD38-Directed Therapies for Management of Multiple Myeloma.ImmunoTargets and therapy · 2021Review
- Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients.CPT: pharmacometrics & systems pharmacology · 2020Article
- Review
- CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity.Frontiers in immunology · 2020Review
- Review
- Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.Leukemia & lymphoma · 2018Review
- CAR T cell therapy for multiple myeloma: where are we now and where are we headed?Leukemia & lymphoma · 2018Review
- NAD Metabolism in Cancer Therapeutics.Frontiers in oncology · 2018Review
- Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.Frontiers in immunology · 2018Review
- Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma.Antibodies (Basel, Switzerland) · 2017Review
- Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.Haematologica · 2017Article
- Review
- Aggressive Plasmablastic Myeloma with Retroperitoneal Extramedullary Plasmacytoma.Kansas journal of medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, the monoclonal antibody daratumumab was approved as a single agent for the treatment of patients with relapsed/refractory Multiple Myeloma (MM). Daratumumab is an antibody targeting surface molecule CD38 on myeloma cells and the agent is already widely being used based on its good tolerability and proven efficacy. We believe, however, that the efficacy of this drug and other anti-CD38 monoclonal antibodies can be further improved by combining it with other types of immunotherapies. Furthermore, surface molecule CD38 can be used as a target for immunotherapies other than just naked monoclonal antibodies. In this report, we review the expression pattern of CD38 among normal tissues and in different types of plasma cell dyscrasias including their progenitor cells, minimal residual disease, and circulating tumor cells. We summarize the physiological role of CD38 as well as its role in the pathophysiology of MM and we present the most recent clinical trials using CD38 as a target. In addition, we highlight possible combination immunotherapies incorporating anti-CD38 monoclonal antibodies and we demonstrate alternative immunotherapeutic approaches targeting the same antigen such as CD38-specific chimeric antigen receptor (CAR) T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.